CML patient characteristics (n = 19).

No, patient number; dg, diagnosis; CML; chronic myeloid leukemia; CP, chronic phase; auto-PBSCT, autologous peripheral blood stem cell transplantation; F, female; M, male; IFN-α, interferon-α; IR, intermediate risk; LR, low risk; MCyR, major cytogenetic response, CCyR, complete cytogenetic response; CMR, complete molecular response; MMR, major molecular response; cont, continues; HLA, human leukocyte antigen; PR1, a peptide for proteinase-3; ND, not done.aAge at diagnosis;bcourse of therapy; all patients were pretreated with hydroxyurea if not otherwise mentioned;cauto-PBSCT, priming miniICE, conditioning high-dose busulfan;dbusulfan sequential therapy regimen after pre-treatment with hydroxyurea;eIFN-α administration in CML-8 protocol (combined with peroral cytarabine at the start);fpercentage of PR-1 specific cells from CD8+ T-cells.